Factor VIII
Coagulation factor VIII; FVIII
Factor VIII (FVIII) is an essential blood coagulation protein, is a key component of the fluid phase blood coagulation system. Factor VIII is also a large procoagulant glycoprotein and a metal ion-dependent heterodimer that circulates in plasma in a noncovalent complex with von Willebrand factor. Factor VIII absence causes a severe bleeding disorder.
References:
- [1]. Mazurkiewicz-Pisarek A, et al. The factor VIII protein and its function. Acta Biochim Pol. 2016;63(1):11-16. [Content Brief]
- [2]. Fay PJ, Jenkins PV. Mutating factor VIII: lessons from structure to function. Blood Rev. 2005 Jan;19(1):15-27. [Content Brief]
- [3]. Hoyer LW. Molecular pathology and immunology of factor VIII (hemophilia A and factor VIII inhibitors). Hum Pathol. 1987 Feb;18(2):153-61. [Content Brief]
All Product Categories
-
Factor VIII Related Products (10)
-
Emicizumab
0 ImagesSynonyms: ACE-910; RG6013Emicizumab is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research.
-
Latarcibart
0 ImagesCat. No.: HY-P991694CAS No.: 3036400-21-9Synonyms: VGA-039Latarcibart is an anti-protein S monoclonal antibody.Latarcibart can be used for the research of bleeding disorders.
-
Emicizumab (Anti-F9 & Factor IX)
0 ImagesCat. No.: HY-P9940APurity: 99.69%Emicizumab (Anti-F9 & Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab (Anti-F9 & Factor IX) can be used for hemophilia A research.
-
Omfiloctocog alfa
0 ImagesCat. No.: HY-P99769CAS No.: 2249927-58-8Synonyms: SCT-800Omfiloctocog alfa (SCT-800) is a recombinant factor VIII (FVIII). FVIII is an essential blood coagulation protein and a key component of the fluid phase blood coagulation system. Omfiloctocog alfa can be used for the research of Hemophilia A.
-
Efmoroctocog alfa
0 ImagesCat. No.: HY-112998CAS No.: 1270012-79-7Synonyms: BIIB-031Efmoroctocog alfa is a recombinant factor VIII-Fc fusion protein (rFVIIIFc). In mice with hemophilia A, Efmoroctocog alfa provides longer-lasting protection against tail vein transection injury than conventional rFVIII products. In dogs with hemophilia A, Efmoroctocog alfa produces a longer duration of improvement in whole blood clotting time than conventional rFVIII products. Efmoroctocog alfa can be used for research on hemophilia A.
-
Neutrophil elastase-IN-7
0 ImagesNeutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC50 value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC50 values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.
-
Turoctocog alfa pegol
0 ImagesCat. No.: HY-114128CAS No.: 1192451-26-5Synonyms: NN-7088; NN 7170Turoctocog alfa pegol is a recombinant coagulation factor VIII (FVIII) from chinese hamster ovary (CHO) cells. Turoctocog alfa pegol can be used for researching haemophilia A.
-
FXIIIa-IN-1
0 ImagesCat. No.: HY-162654CAS No.: 55909-92-7FXIIIa-IN-1 (Compound 16) is a potent and selective FXIIIa (Factor XIIIa) inhibitor with an IC50 value of 2.4 μM. FXIIIa-IN-1 inhibits FXIIIa by competing with the Gln-donor protein substrate (dimethylcasein). FXIIIa-IN-1 holds promise for the development of effective and safe novel anticoagulants.
-
TB-402
0 ImagesCat. No.: HY-P991516TB-402, a human IgG4 anticoagulant monoclonal antibody, is a partial Factor VIII inhibitor. TB-402 has a prolonged antithrombotic effect. TB-402 can be used for the prevention of venous thromboembolism (VTE) after total knee replacement (TKR).
-
Octocog alfa
0 ImagesCat. No.: HY-112865CAS No.: 139076-62-3Synonyms: ADVATE; BAY 81-8973; KovaltryOctocog alfa (ADVATE; BAY 81-8973; Kovaltry) is a standard half-length recombinant coagulation factor FVIII replacement therapy that also functions as a thrombin generation modulator. Octocog alfa regulates thrombin generation-related parameters in vitro and is used in studies related to severe hemophilia A.
